Internal Medicine, Pulmonary Disease · Honolulu, HI
NPI
1013911734
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
321 N Kuakini St, Ste 502
Honolulu, HI, 96817
Phone (808) 531-9753
Medicare paid, 2024
$47K
801 services
Medicare patients, 2024
438
Average age 78
Drug cost, 2024
$642K
2,361 prescriptions
Company payments, 2024
$31.28
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Stuart Sugihara was code 99213 (office e&m - established), 697 times for 415 patients. In total Stuart Sugihara billed 801 services in 8 codes, and Medicare paid $47K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-08-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 697 | 415 | $59.26 | $41K |
| 99214 Office E&M - Established | Office | 48 | 41 | $83.95 | $4,030 |
| 94060 Pulmonary Function Testing | Facility | 15 | 15 | $6.90 | $103 |
| 94727 Pulmonary Function Testing | Facility | 15 | 15 | $8.06 | $121 |
| 99203 Office E&M - New | Office | 11 | 11 | $50.93 | $560 |
By year: 2022 $61K for 955 services; 2023 $60K for 906 services; 2024 $47K for 801 services.
Medicare prescription drug claims, 2024
In 2024, the drug Stuart Sugihara prescribed most often to Medicare patients was Montelukast Sodium, with 555 prescriptions and refills. In total Stuart Sugihara wrote 2,361 Medicare prescriptions that cost $642K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 555 | 1,600 | 174 | $23K |
| Prednisone Generic | 374 | 404 | 172 | $1,028 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 274 | 338 | 113 | $7,151 |
| Breo Ellipta Fluticasone/Vilanterol | 216 | 332 | 41 | $128K |
| Wixela Inhub Fluticasone Propion/Salmeterol | 209 | 411 | 60 | $46K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 133 | 224 | 30 | $140K |
| Ipratropium Bromide Generic | 70 | 102 | 25 | $2,649 |
| Dulera Mometasone/Formoterol | 54 | 100 | 22 | $31K |
| Arnuity Ellipta Fluticasone Furoate | 45 | 59 | Under 11 | $16K |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 43 | 81 | 14 | $49K |
| Advair Hfa Fluticasone Propion/Salmeterol | 37 | 57 | Under 11 | $24K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 32 | 48 | Under 11 | $22K |
| Azithromycin Generic | 32 | 32 | 28 | $366 |
| Fluticasone Propionate Generic | 24 | 70 | 12 | $2,347 |
| Incruse Ellipta Umeclidinium Bromide | 21 | 23 | Under 11 | $7,799 |
Brand drugs: 875 claims; generic drugs: 1,486 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Stuart Sugihara $31.28 ($31.28 in general payments such as food, travel and fees) from 1 company. The largest payer was GlaxoSmithKline, LLC. with $31.28.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 2 | $31.28 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.